{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:11:47Z","timestamp":1790611907489,"version":"4.1.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T00:00:00Z","timestamp":1725926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T00:00:00Z","timestamp":1725926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Cancer"],"DOI":"10.1038\/s43018-024-00822-0","type":"journal-article","created":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T06:24:46Z","timestamp":1725949486000},"page":"1465-1478","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Neoadjuvant gemcitabine\u2013cisplatin plus tislelizumab in persons with resectable muscle-invasive bladder cancer: a multicenter, single-arm, phase 2 trial"],"prefix":"10.1038","volume":"5","author":[{"given":"Kaiwen","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenlong","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhai","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaogang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dexin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaju","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoxu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longhao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaijie","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiquan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyou","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luping","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sentai","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longfei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1296-9316","authenticated-orcid":false,"given":"Jian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3180-8697","authenticated-orcid":false,"given":"Tianxin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,10]]},"reference":[{"key":"822_CR1","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1016\/S0140-6736(16)30512-8","volume":"388","author":"AM Kamat","year":"2016","unstructured":"Kamat, A. M. et al. Bladder cancer. Lancet 388, 2796\u20132810 (2016).","journal-title":"Lancet"},{"key":"822_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","volume":"85","author":"J Alfred Witjes","year":"2024","unstructured":"Alfred Witjes, J. et al. European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2023 guidelines. Eur. Urol. 85, 17\u201331 (2024).","journal-title":"Eur. Urol."},{"key":"822_CR3","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1158\/1078-0432.CCR-20-2409","volume":"27","author":"TW Flaig","year":"2021","unstructured":"Flaig, T. W. et al. A randomized phase II study of coexpression extrapolation (COXEN) with neoadjuvant chemotherapy for bladder cancer (SWOG S1314; NCT02177695). Clin. Cancer Res. 27, 2435\u20132441 (2021).","journal-title":"Clin. Cancer Res."},{"key":"822_CR4","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.eururo.2014.09.007","volume":"67","author":"H Zargar","year":"2015","unstructured":"Zargar, H. et al. Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur. Urol. 67, 241\u2013249 (2015).","journal-title":"Eur. Urol."},{"key":"822_CR5","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.clgc.2020.02.014","volume":"18","author":"G Iyer","year":"2020","unstructured":"Iyer, G. et al. Neoadjuvant gemcitabine\u2013cisplatin plus radical cystectomy\u2013pelvic lymph node dissection for muscle-invasive bladder cancer: a 12-year experience. Clin. Genitourin. Cancer 18, 387\u2013394 (2020).","journal-title":"Clin. Genitourin. Cancer"},{"key":"822_CR6","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1038\/s41591-019-0628-7","volume":"25","author":"T Powles","year":"2019","unstructured":"Powles, T. et al. Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. Nat. Med. 25, 1706\u20131714 (2019).","journal-title":"Nat. Med."},{"key":"822_CR7","doi-asserted-by":"publisher","first-page":"3353","DOI":"10.1200\/JCO.18.01148","volume":"36","author":"A Necchi","year":"2018","unstructured":"Necchi, A. et al. Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study. J. Clin. Oncol. 36, 3353\u20133360 (2018).","journal-title":"J. Clin. Oncol."},{"key":"822_CR8","doi-asserted-by":"publisher","first-page":"5384","DOI":"10.1158\/1078-0432.CCR-14-1298","volume":"20","author":"AR de Biasi","year":"2014","unstructured":"de Biasi, A. R., Villena-Vargas, J. & Adusumilli, P. S. Cisplatin-induced antitumor immunomodulation: a review of preclinical and clinical evidence. Clin. Cancer Res. 20, 5384\u20135391 (2014).","journal-title":"Clin. Cancer Res."},{"key":"822_CR9","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1200\/JCO.21.01003","volume":"39","author":"TL Rose","year":"2021","unstructured":"Rose, T. L. et al. Phase II study of gemcitabine and split-dose cisplatin plus pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive bladder cancer. J. Clin. Oncol. 39, 3140\u20133148 (2021).","journal-title":"J. Clin. Oncol."},{"key":"822_CR10","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1200\/JCO.21.01485","volume":"40","author":"SA Funt","year":"2022","unstructured":"Funt, S. A. et al. Neoadjuvant atezolizumab with gemcitabine and cisplatin in patients with muscle-invasive bladder cancer: a multicenter, single-arm, phase II trial. J. Clin. Oncol. 40, 1312\u20131322 (2022).","journal-title":"J. Clin. Oncol."},{"key":"822_CR11","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s00262-018-2160-x","volume":"67","author":"T Zhang","year":"2018","unstructured":"Zhang, T. et al. The binding of an anti-PD-1 antibody to Fc\u03b3R\u0399 has a profound impact on its biological functions. Cancer Immunol. Immunother. 67, 1079\u20131090 (2018).","journal-title":"Cancer Immunol. Immunother."},{"key":"822_CR12","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/cas.14681","volume":"112","author":"D Ye","year":"2021","unstructured":"Ye, D. et al. Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma. Cancer Sci. 112, 305\u2013313 (2021).","journal-title":"Cancer Sci."},{"key":"822_CR13","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","volume":"171","author":"AG Robertson","year":"2017","unstructured":"Robertson, A. G. et al. Comprehensive molecular characterization of muscle-Invasive bladder cancer. Cell 171, 540\u2013556 (2017).","journal-title":"Cell"},{"key":"822_CR14","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.eururo.2015.07.009","volume":"68","author":"ER Plimack","year":"2015","unstructured":"Plimack, E. R. et al. Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer. Eur. Urol. 68, 959\u2013967 (2015).","journal-title":"Eur. Urol."},{"key":"822_CR15","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1158\/2159-8290.CD-14-0623","volume":"4","author":"EM Van Allen","year":"2014","unstructured":"Van Allen, E. M. et al. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov. 4, 1140\u20131153 (2014).","journal-title":"Cancer Discov."},{"key":"822_CR16","doi-asserted-by":"publisher","first-page":"4025","DOI":"10.1158\/1078-0432.CCR-21-0575","volume":"27","author":"E Adib","year":"2021","unstructured":"Adib, E. et al. CDKN2A alterations and response to immunotherapy in solid tumors. Clin. Cancer Res. 27, 4025\u20134035 (2021).","journal-title":"Clin. Cancer Res."},{"key":"822_CR17","doi-asserted-by":"publisher","first-page":"eabi9533","DOI":"10.1126\/sciadv.abi9533","volume":"8","author":"Q Huang","year":"2022","unstructured":"Huang, Q. et al. Loss of TSC1\/TSC2 sensitizes immune checkpoint blockade in non-small cell lung cancer. Sci. Adv. 8, eabi9533 (2022).","journal-title":"Sci. Adv."},{"key":"822_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-2539-4","volume":"11","author":"Q Lu","year":"2020","unstructured":"Lu, Q. et al. Rheb1 protects against cisplatin-induced tubular cell death and acute kidney injury via maintaining mitochondrial homeostasis. Cell Death Dis. 11, 364 (2020).","journal-title":"Cell Death Dis."},{"key":"822_CR19","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1200\/JCO.2017.75.7740","volume":"36","author":"MY Teo","year":"2018","unstructured":"Teo, M. Y. et al. Alterations in DNA damage response and repair genes as potential marker of clinical benefit from PD-1\/PD-L1 blockade in advanced urothelial cancers. J. Clin. Oncol. 36, 1685\u20131694 (2018).","journal-title":"J. Clin. Oncol."},{"key":"822_CR20","doi-asserted-by":"publisher","first-page":"3610","DOI":"10.1158\/1078-0432.CCR-16-2520","volume":"23","author":"MY Teo","year":"2017","unstructured":"Teo, M. Y. et al. DNA damage response and repair gene alterations are associated with improved survival in patients with platinum-treated advanced urothelial carcinoma. Clin. Cancer Res. 23, 3610\u20133618 (2017).","journal-title":"Clin. Cancer Res."},{"key":"822_CR21","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","volume":"41","author":"KE de Visser","year":"2023","unstructured":"de Visser, K. E. & Joyce, J. A. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell 41, 374\u2013403 (2023).","journal-title":"Cancer Cell"},{"key":"822_CR22","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1080\/1061186X.2017.1306535","volume":"25","author":"B Tian","year":"2017","unstructured":"Tian, B. et al. Curcumin inhibits urothelial tumor development by suppressing IGF2 and IGF2-mediated PI3K\/AKT\/mTOR signaling pathway. J. Drug Target. 25, 626\u2013636 (2017).","journal-title":"J. Drug Target."},{"key":"822_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24919-7","volume":"12","author":"R Das","year":"2021","unstructured":"Das, R. et al. An integrated functional and clinical genomics approach reveals genes driving aggressive metastatic prostate cancer. Nat. Commun. 12, 4601 (2021).","journal-title":"Nat. Commun."},{"key":"822_CR24","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13046-023-02641-0","volume":"42","author":"C De Vitis","year":"2023","unstructured":"De Vitis, C. et al. ALDOC- and ENO2-driven glucose metabolism sustains 3D tumor spheroids growth regardless of nutrient environmental conditions: a multi-omics analysis. J. Exp. Clin. Canc. Res. 42, 69 (2023).","journal-title":"J. Exp. Clin. Canc. Res."},{"key":"822_CR25","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.biopha.2014.02.002","volume":"68","author":"R Januchowski","year":"2014","unstructured":"Januchowski, R. et al. Drug transporter expression profiling in chemoresistant variants of the A2780 ovarian cancer cell line. Biomed. Pharmacother. 68, 447\u2013453 (2014).","journal-title":"Biomed. Pharmacother."},{"key":"822_CR26","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.drup.2007.01.003","volume":"10","author":"S Maddika","year":"2007","unstructured":"Maddika, S. et al. Cell survival, cell death and cell cycle pathways are interconnected: implications for cancer therapy. Drug Resist. Updat. 10, 13\u201329 (2007).","journal-title":"Drug Resist. Updat."},{"key":"822_CR27","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","volume":"160","author":"MS Rooney","year":"2015","unstructured":"Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G. & Hacohen, N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160, 48\u201361 (2015).","journal-title":"Cell"},{"key":"822_CR28","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","volume":"77","author":"A Kamoun","year":"2020","unstructured":"Kamoun, A. et al. A consensus molecular classification of muscle-invasive bladder cancer. Eur. Urol. 77, 420\u2013433 (2020).","journal-title":"Eur. Urol."},{"key":"822_CR29","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan, S. et al. TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554, 544\u2013548 (2018).","journal-title":"Nature"},{"key":"822_CR30","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.1111\/jcmm.16393","volume":"25","author":"Z Liu","year":"2021","unstructured":"Liu, Z. et al. TTN\/OBSCN \u2018double\u2010hit\u2019 predicts favourable prognosis, \u2018immune\u2010hot\u2019 subtype and potentially better immunotherapeutic efficacy in colorectal cancer. J. Cell. Mol. Med. 25, 3239\u20133251 (2021).","journal-title":"J. Cell. Mol. Med."},{"key":"822_CR31","doi-asserted-by":"publisher","first-page":"e2013201","DOI":"10.1001\/jamanetworkopen.2020.13201","volume":"3","author":"L Zhang","year":"2020","unstructured":"Zhang, L., Han, X. & Shi, Y. Association of MUC16 mutation with response to immune checkpoint inhibitors in solid tumors. JAMA Netw. Open 3, e2013201 (2020).","journal-title":"JAMA Netw. Open"},{"key":"822_CR32","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/j.cell.2017.10.049","volume":"171","author":"A Subramanian","year":"2017","unstructured":"Subramanian, A. et al. A next generation connectivity map: L1000 platform and the first 1,000,000 profiles. Cell 171, 1437\u20131452 (2017).","journal-title":"Cell"},{"key":"822_CR33","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1158\/1078-0432.CCR-23-1916","volume":"30","author":"BA Carneiro","year":"2024","unstructured":"Carneiro, B. A. et al. Phase I study of elraglusib (9-ING-41), a glycogen synthase kinase-3\u03b2 inhibitor, as monotherapy or combined with chemotherapy in patients with advanced malignancies. Clin. Cancer Res. 30, 522\u2013531 (2024).","journal-title":"Clin. Cancer Res."},{"key":"822_CR34","doi-asserted-by":"publisher","first-page":"e006643","DOI":"10.1136\/jitc-2022-006643","volume":"11","author":"Y Song","year":"2023","unstructured":"Song, Y. et al. Fibroblast growth factor receptor 3 mutation attenuates response to immune checkpoint blockade in metastatic urothelial carcinoma by driving immunosuppressive microenvironment. J. Immunother. Cancer 11, e006643 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"822_CR35","doi-asserted-by":"publisher","first-page":"5131","DOI":"10.1200\/JCO.23.00363","volume":"41","author":"R Cathomas","year":"2023","unstructured":"Cathomas, R. et al. Perioperative chemoimmunotherapy with durvalumab for muscle-invasive urothelial carcinoma: primary analysis of the single-arm phase II trial SAKK 06\/17. J. Clin. Oncol. 41, 5131\u20135139 (2023).","journal-title":"J. Clin. Oncol."},{"key":"822_CR36","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1200\/JCO.2023.41.6_suppl.448","volume":"41","author":"J Brown","year":"2023","unstructured":"Brown, J. et al. HCRN GU14-188: phase Ib\/II study of neoadjuvant pembrolizumab and chemotherapy for T2-4aN0M0 urothelial cancer. J. Clin. Oncol. 41, 448\u2013448 (2023).","journal-title":"J. Clin. Oncol."},{"key":"822_CR37","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1200\/JCO.2020.38.6_suppl.439","volume":"38","author":"S Gupta","year":"2020","unstructured":"Gupta, S. et al. Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle invasive bladder cancer (MIBC) undergoing cystectomy. J. Clin. Oncol. 38, 439\u2013439 (2020).","journal-title":"J. Clin. Oncol."},{"key":"822_CR38","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/S1470-2045(21)00152-2","volume":"22","author":"T Powles","year":"2021","unstructured":"Powles, T. et al. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Lancet Oncol. 22, 931\u2013945 (2021).","journal-title":"Lancet Oncol."},{"key":"822_CR39","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/S1470-2045(23)00539-9","volume":"25","author":"A Bamias","year":"2024","unstructured":"Bamias, A. et al. Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study. Lancet Oncol. 25, 46\u201361 (2024).","journal-title":"Lancet Oncol."},{"key":"822_CR40","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","volume":"389","author":"MS Van Der Heijden","year":"2023","unstructured":"Van Der Heijden, M. S. et al. Nivolumab plus gemcitabine\u2013cisplatin in advanced urothelial carcinoma. N. Engl. J. Med. 389, 1778\u20131789 (2023).","journal-title":"N. Engl. J. Med."},{"key":"822_CR41","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","volume":"384","author":"DF Bajorin","year":"2021","unstructured":"Bajorin, D. F. et al. Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N. Engl. J. Med. 384, 2102\u20132114 (2021).","journal-title":"N. Engl. J. Med."},{"key":"822_CR42","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.eururo.2022.04.013","volume":"82","author":"B Szabados","year":"2022","unstructured":"Szabados, B. et al. Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder. Eur. Urol. 82, 212\u2013222 (2022).","journal-title":"Eur. Urol."},{"key":"822_CR43","doi-asserted-by":"publisher","first-page":"3633","DOI":"10.1158\/1078-0432.CCR-22-3769","volume":"29","author":"MD Galsky","year":"2023","unstructured":"Galsky, M. D. et al. Determinants of survival with combined HER2 and PD-1 blockade in metastatic esophagogastric cancer. Clin. Cancer Res. 29, 3633\u20133640 (2023).","journal-title":"Clin. Cancer Res."},{"key":"822_CR44","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1093\/annonc\/mdu126","volume":"25","author":"H Kitamura","year":"2014","unstructured":"Kitamura, H. et al. Randomised phase III study of neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine and cisplatin followed by radical cystectomy compared with radical cystectomy alone for muscle-invasive bladder cancer: Japan Clinical Oncology Group Study JCOG0209. Ann. Oncol. 25, 1192\u20131198 (2014).","journal-title":"Ann. Oncol."},{"key":"822_CR45","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1056\/NEJMoa022148","volume":"349","author":"HB Grossman","year":"2003","unstructured":"Grossman, H. B. et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N. Engl. J. Med. 349, 859\u2013866 (2003).","journal-title":"N. Engl. J. Med."},{"key":"822_CR46","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.eururo.2023.07.014","volume":"85","author":"T Strandgaard","year":"2024","unstructured":"Strandgaard, T. et al. Field cancerization is associated with tumor development, T-cell exhaustion, and clinical outcomes in bladder cancer. Eur. Urol. 85, 82\u201392 (2024).","journal-title":"Eur. Urol."},{"key":"822_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37568-9","volume":"14","author":"AG Robertson","year":"2023","unstructured":"Robertson, A. G. et al. Expression-based subtypes define pathologic response to neoadjuvant immune-checkpoint inhibitors in muscle-invasive bladder cancer. Nat. Commun. 14, 2126 (2023).","journal-title":"Nat. Commun."},{"key":"822_CR48","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/j.cell.2017.11.013","volume":"171","author":"RM Kortlever","year":"2017","unstructured":"Kortlever, R. M. et al. Myc cooperates with Ras by programming inflammation and immune suppression. Cell 171, 1301\u20131315 (2017).","journal-title":"Cell"},{"key":"822_CR49","doi-asserted-by":"publisher","first-page":"102123","DOI":"10.1016\/j.eclinm.2023.102123","volume":"62","author":"X Fang","year":"2023","unstructured":"Fang, X. et al. Sintilimab plus bevacizumab, oxaliplatin and capecitabine as first-line therapy in RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer: an open-label, single-arm, phase II trial. EClinicalMedicine 62, 102123 (2023).","journal-title":"EClinicalMedicine"},{"key":"822_CR50","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/s41568-019-0143-7","volume":"19","author":"LN Kent","year":"2019","unstructured":"Kent, L. N. & Leone, G. The broken cycle: E2F dysfunction in cancer. Nat. Rev. Cancer 19, 326\u2013338 (2019).","journal-title":"Nat. Rev. Cancer"},{"key":"822_CR51","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1016\/j.cell.2022.03.033","volume":"185","author":"P Baldominos","year":"2022","unstructured":"Baldominos, P. et al. Quiescent cancer cells resist T cell attack by forming an immunosuppressive niche. Cell 185, 1694\u20131708 (2022).","journal-title":"Cell"},{"key":"822_CR52","doi-asserted-by":"publisher","first-page":"5082","DOI":"10.1158\/1078-0432.CCR-18-1106","volume":"25","author":"R Seiler","year":"2019","unstructured":"Seiler, R. et al. Divergent biological response to neoadjuvant chemotherapy in muscle-invasive bladder cancer. Clin. Cancer Res. 25, 5082\u20135093 (2019).","journal-title":"Clin. Cancer Res."},{"key":"822_CR53","doi-asserted-by":"publisher","first-page":"c332","DOI":"10.1136\/bmj.c332","volume":"340","author":"KF Schulz","year":"2010","unstructured":"Schulz, K. F., Altman, D. G., Moher, D. & CONSORT Group CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ 340, c332\u2013c332 (2010).","journal-title":"BMJ"},{"key":"822_CR54","doi-asserted-by":"publisher","first-page":"D1062","DOI":"10.1093\/nar\/gkx1153","volume":"46","author":"MJ Landrum","year":"2018","unstructured":"Landrum, M. J. et al. ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res. 46, D1062\u2013D1067 (2018).","journal-title":"Nucleic Acids Res."},{"key":"822_CR55","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/nmeth0410-248","volume":"7","author":"IA Adzhubei","year":"2010","unstructured":"Adzhubei, I. A. et al. A method and server for predicting damaging missense mutations. Nat. Methods 7, 248\u2013249 (2010).","journal-title":"Nat. Methods"},{"key":"822_CR56","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon, A. et al. The molecular signatures database hallmark gene set collection. Cell Syst. 1, 417\u2013425 (2015).","journal-title":"Cell Syst."},{"key":"822_CR57","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-017-1349-1","volume":"18","author":"D Aran","year":"2017","unstructured":"Aran, D., Hu, Z. & Butte, A. J. xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 18, 220 (2017).","journal-title":"Genome Biol."},{"key":"822_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3612","volume":"4","author":"K Yoshihara","year":"2013","unstructured":"Yoshihara, K. et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat. Commun. 4, 2612 (2013).","journal-title":"Nat. Commun."},{"key":"822_CR59","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/ni.2789","volume":"15","author":"S Li","year":"2014","unstructured":"Li, S. et al. Molecular signatures of antibody responses derived from a systems biology study of five human vaccines. Nat. Immunol. 15, 195\u2013204 (2014).","journal-title":"Nat. Immunol."},{"key":"822_CR60","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.immuni.2008.05.012","volume":"29","author":"D Chaussabel","year":"2008","unstructured":"Chaussabel, D. et al. A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus. Immunity 29, 150\u2013164 (2008).","journal-title":"Immunity"},{"key":"822_CR61","doi-asserted-by":"publisher","first-page":"5146","DOI":"10.1093\/bioinformatics\/btz447","volume":"35","author":"J Zyla","year":"2019","unstructured":"Zyla, J. et al. Gene set enrichment for reproducible science: comparison of CERNO and eight other algorithms. Bioinformatics 35, 5146\u20135154 (2019).","journal-title":"Bioinformatics"},{"key":"822_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","volume":"10","author":"R Simon","year":"1989","unstructured":"Simon, R. Optimal two-stage designs for phase II clinical trials. Controlled Clin. Trials 10, 1\u201310 (1989).","journal-title":"Controlled Clin. Trials"}],"container-title":["Nature Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43018-024-00822-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-024-00822-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-024-00822-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T06:02:54Z","timestamp":1729749774000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43018-024-00822-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,10]]},"references-count":62,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["822"],"URL":"https:\/\/doi.org\/10.1038\/s43018-024-00822-0","relation":{},"ISSN":["2662-1347"],"issn-type":[{"value":"2662-1347","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,10]]},"assertion":[{"value":"9 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"L.H. and T.Z. were employees of GloriousMed at the time of the study. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}